How is disease activity monitored in Giant Cell Arteritis?
No disease-specific biomarker is available in GCA. ESR and CRP are utilized along with clinical assessment. The use of imaging, particularly MRA and PET, in disease activity assessment may be reasonable in situations where flare is clinically suspected, although their appropriate use in patients without clinical suspicion of active disease is undetermined. The ideal use and value of these modalities, including validated scoring systems, are active topics of current research.
